taurine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4486 | 107-35-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A conditionally essential nutrient, important during mammalian development. It is present in milk but is isolated mostly from ox bile and strongly conjugates bile acids.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA | ||
| Feb. 21, 2019 | PMDA | TAISHO PHARMACEUTICAL CO., LTD. |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Retinogram abnormal | 27.55 | 24.83 | 4 | 556 | 167 | 63488295 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Retinogram abnormal | 46.32 | 23.72 | 7 | 775 | 346 | 79743260 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| CHEBI has role | CHEBI:22586 | antioxidants |
| CHEBI has role | CHEBI:33284 | nutrients |
| CHEBI has role | CHEBI:48578 | free radical scavengers |
| CHEBI has role | CHEBI:64589 | glycine receptor agonists |
| CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
| CHEBI has role | CHEBI:75772 | S. cerevisiae metabolites |
| CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
| CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Stroke-like episodes in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) | indication | 39925003 | DOID:3687 |
| Nutritional support | indication | 278906000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 0.75 | acidic |
| pKa2 | 9.3 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D00047 | KEGG_DRUG |
| 4018683 | VUID |
| N0000146994 | NUI |
| 4018683 | VANDF |
| CHEBI:15891 | CHEBI |
| TAU | PDB_CHEM_ID |
| CHEMBL239243 | ChEMBL_ID |
| 2379 | IUPHAR_LIGAND_ID |
| 6171 | INN_ID |
| DB01956 | DRUGBANK_ID |
| 1EQV5MLY3D | UNII |
| 10337 | RXNORM |
| 009160 | NDDF |
| 10944007 | SNOMEDCT_US |
| 419158001 | SNOMEDCT_US |
| C0039350 | UMLSCUI |
| D013654 | MESH_DESCRIPTOR_UI |
| 1123 | PUBCHEM_CID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.03 g | INTRAVENOUS | NDA | 23 sections |
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.03 g | INTRAVENOUS | NDA | 23 sections |
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-1933 | SOLUTION | 0.03 g | INTRAVENOUS | NDA | 23 sections |
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9341 | SOLUTION | 0.03 g | INTRAVENOUS | NDA | 23 sections |
| TrophAmine | HUMAN PRESCRIPTION DRUG LABEL | 20 | 0264-9361 | SOLUTION | 0.02 g | INTRAVENOUS | NDA | 23 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1130 | INJECTION, SOLUTION | 25 mg | INTRAVENOUS | ANDA | 15 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1130 | INJECTION, SOLUTION | 25 mg | INTRAVENOUS | ANDA | 15 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1130 | INJECTION, SOLUTION | 25 mg | INTRAVENOUS | ANDA | 15 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1131 | INJECTION, SOLUTION | 15 mg | INTRAVENOUS | ANDA | 15 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1131 | INJECTION, SOLUTION | 15 mg | INTRAVENOUS | ANDA | 15 sections |
| Premasol - sulfite-free (Amino Acid) | HUMAN PRESCRIPTION DRUG LABEL | 19 | 0338-1131 | INJECTION, SOLUTION | 15 mg | INTRAVENOUS | ANDA | 15 sections |
| Aminosyn-PF | HUMAN PRESCRIPTION DRUG LABEL | 18 | 0409-4178 | INJECTION, SOLUTION | 50 mg | INTRAVENOUS | NDA | 14 sections |
| Aminosyn-PF | HUMAN PRESCRIPTION DRUG LABEL | 18 | 0990-4178 | INJECTION, SOLUTION | 50 mg | INTRAVENOUS | NDA | 13 sections |
| Aminosyn-PF | HUMAN PRESCRIPTION DRUG LABEL | 18 | 0990-4178 | INJECTION, SOLUTION | 50 mg | INTRAVENOUS | NDA | 13 sections |
| Aminosyn-PF | HUMAN PRESCRIPTION DRUG LABEL | 18 | 0990-4179 | INJECTION, SOLUTION | 70 mg | INTRAVENOUS | NDA | 14 sections |
| Aminosyn-PF | HUMAN PRESCRIPTION DRUG LABEL | 18 | 0990-4179 | INJECTION, SOLUTION | 70 mg | INTRAVENOUS | NDA | 14 sections |
| Ginsamin Energy | HUMAN OTC DRUG LABEL | 5 | 44738-7001 | LIQUID | 1000 mg | ORAL | unapproved drug other | 6 sections |
| LINGTEA | HUMAN OTC DRUG LABEL | 1 | 72355-0001 | POWDER | 1 g | ORAL | unapproved drug other | 6 sections |